LTRN: Lantern Pharma Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 42.92
Enterprise Value ($M) 35.41
Book Value ($M) 21.19
Book Value / Share 1.96
Price / Book 2.03
NCAV ($M) 20.86
NCAV / Share 1.93
Price / NCAV 2.06

Profitability (mra)
Return on Invested Capital (ROIC) -0.97
Return on Assets (ROA) -0.52
Return on Equity (ROE) -0.58

Liquidity (mrq)
Quick Ratio 5.83
Current Ratio 5.83

Balance Sheet (mrq) ($M)
Current Assets 25.25
Assets 25.57
Liabilities 4.38
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -22.22
Net Income -20.78

Cash Flow Statement (mra) ($M)
Cash From Operations -17.81
Cash from Investing 3.37
Cash from Financing 0.07

(click for more detail)
Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-04-30 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSI
2025-03-27 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUA
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPO
2024-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PU

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-05-09 7,915 20,280 39.03
2025-05-08 11,035 44,004 25.08
2025-05-07 47,405 143,543 33.02
2025-05-06 15,162 42,632 35.56
2025-05-05 13,344 43,956 30.36

(click for more detail)

Similar Companies
LPTX – Leap Therapeutics, Inc. LQDA – Liquidia Corporation
LSTA – Lisata Therapeutics, Inc. MBIO – Mustang Bio, Inc.
MBRX – Moleculin Biotech, Inc.


Financial data and stock pages provided by
Fintel.io